Item 8.01. Other Events
On January 8, 2020, Edesa Biotech, Inc. (the "Company") closed its previously
announced registered direct offering of 1,354,691 common shares, no par value
(the "Common Shares") and concurrent private placement of Class A Purchase
Warrants to purchase an aggregate of up to 1,016,036 Common Shares and Class B
Purchase Warrants to purchase an aggregate of up to 677,358 Common Shares. The
Company expects to receive aggregate gross proceeds in the offering of
approximately $4.36 million, before deducting fees to the placement agent and
other estimated offering expenses payable by the Company. Following the closing,
the Company has 8,859,159 Common Shares issued and outstanding.
© Edgar Online, source Glimpses
